Guest guest Posted July 13, 2010 Report Share Posted July 13, 2010 HCV Drug BMS-790052 Great Blog Check it Out l The ubiquitous Jules Levin posts slides giving a resistance overview of the highly touted BMS-790052 compound presented at the recent HCV Drug Resistance New Compounds Workshop in Boston, MA. See it all here: http://www.natap.org/2010/HCVresist/HCVresist_07.htm So far, this is what we know:* Once-daily NS5A Inhibitor* Used in combo with P/R, there is an additive effect. Looks to be a good candidate for combination therapy as well - when used in combo with BMS NS5B inhibitor, BMS NS3 inhibitor and an unnamed nuc, there are both additive and synergistic effects. l* Blocks multiple stages of viral replication - inactivation of NS5A appears to take out a whole communication network between NS5A's, as they communicate with each other in a replication network. l* Nice correlation between in vitro and in vivo resistance. No surprises.* Is there pre-existing resistance? Yep. Like the linear NS3 PIs, it appears that G1a virus are inherently more resistant to BMS-790052 than G1b. BMS suggests that "NS5A baseline sequences may provide useful information for predicting resistance emergence". l* Another big question for BMS-790052, as is for the other drugs in development, is drug interactions. As we've seen in HIV antiretroviral therapy, drug interactions are extremely important to know to prevent adverse events and fluctuations in pharmacokinetics that may compromise efficacy and lead to emergence of resistant virus. l Source http://Hepatitis Cnewdrugs.blogspot.com/2010/07/hcv-drug-bms-790052.html Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.